



LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
DEBRA J. MILASINCIC, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPPERT  
JOHN D. LANZA  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
HATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
MICHAEL J. BASTIAN, Ph.D.  
CHRISTOPHER J. McKENNA  
VINCENT P. LOCCISANO  
JAMES M. MCKENZIE  
CYNTHIA M. GILBERT  
LEIGH J. MARTINSON  
JILL R. GORNY

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.  
CHRISTOPHER E. DRABIK  
JAMES H. VELEMA  
JACOB G. WEINTRAUB  
BRIAN C. TRINQUE, Ph.D.

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
DEBORAH L. NAGLE, Ph.D.  
ANNE JACQUELINE WIZEMAN, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.  
W. ELANA WANG  
MEAGHAN L. RICHMOND, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

IFW

April 4, 2005

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/807,911  
For: *METHODS FOR TREATING MULTIPLE SCLEROSIS*  
Inventors: L. Sai Latha Shankar, *et al.*  
Filed: March 23, 2004  
Our Ref. No.: WTZ-010CPACN2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to:  
MS Amendment, Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450 on:

April 4, 2005

Date

Cynthia M. Soroos, Esq. Registration No. 53,623

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos, Esq.  
Registration No. 53,623  
Attorney for Applicants



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/807,911
				Filing Date	March 23, 2004
				First Named Inventor	L.Sai Latha Shankar
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	WTZ-010CPACN2


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	5,444,095	08-22-1995	Tatton <i>et al.</i>	
	A2	5,767,164	06-16-1998	Tatton <i>et al.</i>	
	A3	5,844,003	12-01-1998	Tatton <i>et al.</i>	
	A4	6,492,427	12-10-2002	Shankar <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A5	WO 96/40095 A1	12-19-1996	Harris, Richard Y.		
	A6	WO 96/22068 A2	07-25-1996	Somerset Pharmaceuticals		
	A7	WO 97/25421 A2	07-17-1997	Ciba Geigy AG		
	A8	WO 97/28791 A2	08-14-1997	University of Toronto		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A9	Bernheimer, H. <i>et al.</i> (1973) "Brain Dopamine and the Syndromes of Parkinson and Huntington. Clinical, Morphological and Neurochemical Correlations" Journal of the Neurological Sciences 29:415-455;	
	A10	Birkmayer, <i>et al.</i> (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry. 1983;19:170-6.	
	A11	Birkmayer, <i>et al.</i> Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Adv Neurol. 1984;40:475-81.	
	A12	Birkmayer, <i>et al.</i> Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113-27.	
	A13	Birkmayer, <i>et al.</i> The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36(3-4):303-26.	
	A14	Cedarbaum, <i>et al.</i> A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):207-12.	
	A15	Dorland's Illustrated Medical Dictionary, 28 <sup>th</sup> Supp. Edition, 1988, p. 1174.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, the persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/807,911
				Filing Date	March 23, 2004
				First Named Inventor	L.Sai Latha Shankar
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	WTZ-010CPACN2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	B1	Elizan, <i>et al.</i> Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol. 1989 Dec;46(12):1280-3.		
	B2	Fischer, <i>et al.</i> Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm Suppl. 1987;25:137-47.		
	B3	Golbe, Lawrence I. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 1989 Aug;39(8):1109-11.		
	B4	Golbe, <i>et al.</i> Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs. 1990 May;39(5):646-51.		
	B5	Lieberman, <i>et al.</i> Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med. 1987 Dec;87(12):646-9.		
	B6	Mitrovic, <i>et al.</i> An in Vitro Model of Oligodendrocyte Destruction by Nitric Oxide and Its Relevance to Multiple Sclerosis Methods. 1996 Dec;10(3):501-13.		
	B7	Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989 Oct;46(10):1052-60.		
	B8	The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989 Nov 16;321(20):1364-71.		
	B9	Raine, Cedric. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol. 1997 Aug;77(2):135-52.		
	B10	Shankar, S.L. (1995) "R-(-)-Deprenyl Increases Survival and Process Complexity of Oligodendrocytes In Vitro" 25 <sup>th</sup> Annual Meeting of the Society for Neuroscience, San Diego, California, USA, November 11-16, 1995. Society for Neuroscience Abstracts 21(1-3):41;		
	B11	Sketris, <i>et al.</i> Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. Clin Ther. 1996 Mar-Apr;18(2):303-18.		
	B12	Tatton, <i>et al.</i> Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996 Dec;47(6 Suppl 3):S171-83.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: L. Sai Latha Shankar, *et al.*

Serial No.: 10/807,911

Filed: March 23, 2004

For: *METHODS FOR TREATING MULTIPLE SCLEROSIS*

Attorney Docket No.: WTZ-010CPACN2

Group Art Unit: 1645

Examiner: Not Yet Assigned

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

April 4, 2005

Date of Signature and of Mail Deposit

By:

  
Cynthia M. Soroos, Esq.  
Registration No. 53,623  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

For the Examiner's convenience in reviewing this continuation application, Applicants submits a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation of U.S. Serial No. 10/205,747, filed July 26, 2002 (Atty. Docket No. WTZ-010CPACN) which is a Continuation of U.S. Serial No. 09/416,010, filed May 22, 2001 (Atty. Docket No. WTZ-010CPA). References A1, A3, A5-A15, and B1-B12 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request. In addition, this Information Disclosure Statement presents references A2 and A4, not previously submitted to

the Office. Copies of cited U.S. patents (Reference ID Nos. A2 and A4) are not enclosed with this statement in accordance with 37 CFR 1.98.


Applicants bring to the Examiner's attention the following co-pending patent applications:

Serial No.	First Named Inventor	Filing Date
09/416010	William G. Tatton	October 8, 1999
10/205747	William G. Tatton	July 26, 2002

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Cynthia M. Soroos, Esq.  
Registration No. 53,623  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: April 4, 2005

EAH/CMS/MLR/les  
Enclosures